Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ: CRSP )

46.27 +1.87 (+4.21%)
Streaming Delayed Price Updated: 10:27 AM EST, Feb 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
31 32 Next >
2 Top Biotech Stocks to Buy for the Long Haul
These companies have what it takes to grow their revenues -- and their share prices -- over time. 
Via The Motley Fool
If You Invested $10,000 in CRISPR Therapeutics In 2020, This Is How Much You Would Have Today
The stock has been on a wild ride over the past few years. 
Via The Motley Fool
Missed Out on Vertex? My Best Gene-Editing Stock to Buy and Hold
Get in on CRISPR Therapeutics before it gets expensive. 
Via The Motley Fool
2 Healthcare Stocks That Could Help Make You a Fortune
These companies also happen to be a bargain right now. 
Via The Motley Fool
7 Cathie Wood Stocks for Your March Buy List
These top Cathie Wood stocks are just now attempting to pivot higher after a miserable outing for much of 2022. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For March 7, 2023
Via Benzinga
3 CRISPR Gene Editing Stocks to Consider for Ground-Floor Investing
CRISPR Therapeutics, Beam Therapeutics and Vertex Pharmaceuticals are three CRISPR gene editing stocks you won't want to miss out on. 
Via InvestorPlace
Better Growth Stock: Moderna vs. CRISPR Therapeutics
Both stocks are ripe for a rebound. 
Via The Motley Fool
3 Things About CRISPR Therapeutics That Smart Investors Know
Institutional investors might be on to something. 
Via The Motley Fool
3 Game-Changing Stocks to Buy in March
Innovation is in these companies' DNA. 
Via The Motley Fool
2 Soaring Stocks to Buy and Hold Through 2023 and Beyond
Investors are bidding up shares of these companies, and there are good reasons for doing so. 
Via The Motley Fool
10 Best Stocks to Buy in March 2023
These diversified growth stocks could add rocket fuel to your long-term investment portfolio. 
Via The Motley Fool
Expert Ratings for CRISPR Therapeutics
Via Benzinga
Looking Into CRISPR Therapeutics's Return On Invested Capital
Via Benzinga
Beat the Dow Jones With CRISPR Therapeutics Stock
If approved, CRISPR's first product may deliver blockbuster sales. 
Via The Motley Fool
Here's How Much You Can Make From Investing Your Tax Return Every Year
Doing this can strengthen your retirement plan. 
Via The Motley Fool
Better Buy: Beam Therapeutics or Intellia Therapeutics?
The two clinical-stage gene-editing companies have good long-term prospects. 
Via The Motley Fool
2 Bruised Growth Stocks to Buy While They're Cheap
Both are on the verge of fast growth, and they haven't had any major setbacks yet. 
Via The Motley Fool
SMID Cap Life Science Update: Are You An Investor Or Trader?
Despite choppy trading, there is an upward tilt to life science stocks since the 9/26/22 lows. 
Via Talk Markets
2 Marvelous Growth Stocks to Buy Today and Hold for 5 Years or Longer
These two companies are on track to flourish through the end of the decade. 
Via The Motley Fool
These 2 Biotech Stocks Could Soar in the Next Bull Market
They're both at the cutting edge of gene-editing technology. 
Via The Motley Fool
Top CRISPR Stocks
CRISPR is a narrow niche of the biotechnology industry, but it could become the fastest growing and most significant of all the biotech businesses. 
Via Talk Markets
Could CRISPR Therapeutics Stock Help You Become a Millionaire?
The gene-editing business has loads of potential, but is it enough to make you rich? 
Via The Motley Fool
3 Prime Healthcare Takeover Targets
These three companies are attractive targets for their potential. 
Via The Motley Fool
The Best Stocks To Invest $5,000 in Right Now
The time is right for each of these great stocks. 
Via The Motley Fool
These Cheap Growth Stocks Could Supercharge Your Portfolio
All of these players are cheap today considering their growth potential. 
Via The Motley Fool
Is Vertex Pharmaceuticals Stock a Buy Right Now?
The drugmaker outperformed the broad market by a mile in 2022, but could there be further gains? 
Via The Motley Fool
2 Biotech Stocks That Could Make You Richer
Patience will pay off with these two stocks. 
Via The Motley Fool
Better Bull Market Buy: CRISPR Therapeutics or Vertex Pharmaceuticals?
Both stocks should be winners if gene-editing therapy exa-cel wins regulatory approvals. 
Via The Motley Fool
Wall Street Expects This Stock to Jump 70% This Year. Here's Why It Could Happen.
CRISPR shares are ripe for a rebound after dropping 46% last year. 
Via The Motley Fool
< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
31 32 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS